Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
BridgeBio Pharma, Inc. (BBIO) had Income from Continuous Operations of $-169.61M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$116.63M |
|
$-167.42M |
|
$2.64M |
|
$113.99M |
|
$221.00M |
|
$-104.37M |
|
$-65.24M |
|
$-169.61M |
|
$-169.61M |
|
$-169.61M |
|
|
Income from Continuous Operations |
$-169.61M |
$-169.61M |
|
$-169.61M |
|
$-104.37M |
|
$-103.09M |
|
190.15M |
|
190.15M |
|
$-0.88 |
|
$-0.88 |
|
| Balance Sheet Financials | |
$695.17M |
|
$6.70M |
|
$186.47M |
|
$881.64M |
|
$152.10M |
|
$1.85B |
|
$2.37B |
|
$2.52B |
|
$-1.64B |
|
$-1.67B |
|
$-1.64B |
|
189.83M |
|
| Cash Flow Statement Financials | |
$-199.24M |
|
$-1.59M |
|
$60.33M |
|
$683.24M |
|
$542.74M |
|
$-140.50M |
|
$25.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.57 |
|
-- |
|
-- |
|
8.81 |
|
-1.13 |
|
97.74% |
|
-89.49% |
|
-89.49% |
|
-- |
|
-145.42% |
|
-143.55% |
|
$-199.24M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.67 |
|
1.01 |
|
88.94 |
|
10.35% |
|
10.18% |
|
-19.24% |
|
-80.89% |
|
$-8.63 |
|
$-1.05 |
|
$-1.05 |
|